6tpe: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
<StructureSection load='6tpe' size='340' side='right'caption='[[6tpe]], [[Resolution|resolution]] 2.87Å' scene=''> | <StructureSection load='6tpe' size='340' side='right'caption='[[6tpe]], [[Resolution|resolution]] 2.87Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'> | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TPE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TPE FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.87Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NTW:2-[4-(3-methyl-6-oxidanylidene-1,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]ethanenitrile'>NTW</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tpe FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tpe OCA], [https://pdbe.org/6tpe PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tpe RCSB], [https://www.ebi.ac.uk/pdbsum/6tpe PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tpe ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 21: | Line 17: | ||
</div> | </div> | ||
<div class="pdbe-citations 6tpe" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6tpe" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Janus kinase 3D structures|Janus kinase 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Burhardt MN]] | |||
[[Category: Burhardt | [[Category: Carnerup MA]] | ||
[[Category: Carnerup | [[Category: Hansen BB]] | ||
[[Category: Hansen | [[Category: Jepsen TH]] | ||
[[Category: Jepsen | [[Category: Jerre A]] | ||
[[Category: Jerre | [[Category: Jestel A]] | ||
[[Category: Jestel | [[Category: Lammens A]] | ||
[[Category: Lammens | [[Category: Larsen J]] | ||
[[Category: Larsen | [[Category: Larsen M]] | ||
[[Category: Larsen | [[Category: Molck C]] | ||
[[Category: Molck | [[Category: Nasipireddy VR]] | ||
[[Category: Nasipireddy | [[Category: Rai S]] | ||
[[Category: Rai | [[Category: Ritzen A]] | ||
[[Category: Ritzen | [[Category: Seitzberg JG]] | ||
[[Category: Seitzberg | [[Category: Sindet R]] | ||
[[Category: Sindet | [[Category: Vifian T]] | ||
[[Category: Vifian | |||
Latest revision as of 16:09, 6 November 2024
Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivityFragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
Structural highlights
Publication Abstract from PubMedHerein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by the introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound 40, which showed excellent potency and selectivity. Metabolism studies in vitro and in vivo together with an in vitro safety evaluation suggest that 40 may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors. Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.,Hansen BB, Jepsen TH, Larsen M, Sindet R, Vifian T, Burhardt MN, Larsen J, Seitzberg JG, Carnerup MA, Jerre A, Molck C, Lovato P, Rai S, Nasipireddy VR, Ritzen A J Med Chem. 2020 Jun 8. doi: 10.1021/acs.jmedchem.0c00359. PMID:32462873[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|